NLS Pharmaceutics Ltd. Files Form 6-K: Extraordinary Shareholders’ Meeting Announcement

Here's a summary of the key information extracted from the financial report (Form 6-K) of NLS Pharmaceutics Ltd.:

1. Report Type and Filing Details:

• This is a Form 6-K filed by NLS Pharmaceutics Ltd., indicating it is a report of a foreign private issuer.
• The filing date is December 23, 2024.
• Commission File Number: 001-39957.

2. Company Information:

• Registrant Name: NLS Pharmaceutics Ltd.
• Address: The Circle 6, 8058 Zurich, Switzerland.

3. Meeting Announcement:

• An Extraordinary Shareholders’ Meeting is scheduled for January 14, 2025.
• Only shareholders of record who hold common and/or preferred shares as of December 23, 2024, will be entitled to vote.

4. Incorporation of Documents:

• The report is incorporated by reference into the company’s Registration Statements on Form F-3, which includes multiple file numbers related to previous SEC filings.

5. Signatures:

• The report is signed by Alexander C. Zwyer, the Chief Executive Officer of NLS Pharmaceutics Ltd.
• Signature Date: December 23, 2024.

6. Exhibit Index:

• The document includes Exhibit 99.1, which contains the Notice of Meeting and Proxy Card for the Extraordinary Shareholders’ Meeting.

This report serves as an important communication to shareholders regarding the upcoming meeting and voting rights.